Johnson & Johnson (NYSE:JNJ) Shares Acquired by Country Trust Bank

Country Trust Bank increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 4.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 201,872 shares of the company’s stock after purchasing an additional 8,255 shares during the quarter. Country Trust Bank’s holdings in Johnson & Johnson were worth $32,715,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of JNJ. FCF Advisors LLC purchased a new stake in Johnson & Johnson in the 3rd quarter valued at $9,423,000. Sugarloaf Wealth Management LLC grew its holdings in shares of Johnson & Johnson by 2.6% during the third quarter. Sugarloaf Wealth Management LLC now owns 6,378 shares of the company’s stock worth $1,034,000 after buying an additional 164 shares during the last quarter. Park Place Capital Corp increased its position in Johnson & Johnson by 22.9% in the 3rd quarter. Park Place Capital Corp now owns 5,976 shares of the company’s stock valued at $968,000 after acquiring an additional 1,112 shares during the period. Atomi Financial Group Inc. raised its stake in Johnson & Johnson by 10.7% during the 3rd quarter. Atomi Financial Group Inc. now owns 44,410 shares of the company’s stock valued at $7,197,000 after acquiring an additional 4,288 shares during the last quarter. Finally, Marion Wealth Management acquired a new stake in Johnson & Johnson during the 3rd quarter worth approximately $236,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the transaction, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is owned by insiders.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $159.64 on Wednesday. The firm has a market cap of $384.20 billion, a price-to-earnings ratio of 9.95, a price-to-earnings-growth ratio of 2.69 and a beta of 0.52. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $168.85. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. The company’s 50-day moving average is $162.62 and its two-hundred day moving average is $154.33.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, topping the consensus estimate of $2.71 by $0.11. The firm had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. Johnson & Johnson’s revenue for the quarter was up 4.3% on a year-over-year basis. During the same period in the previous year, the company earned $2.80 EPS. Research analysts expect that Johnson & Johnson will post 10.02 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were issued a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, August 27th. This represents a $4.96 annualized dividend and a dividend yield of 3.11%. Johnson & Johnson’s payout ratio is currently 30.92%.

Analysts Set New Price Targets

JNJ has been the topic of several recent research reports. Daiwa Capital Markets cut shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and dropped their price objective for the company from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Sanford C. Bernstein lifted their price objective on Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. The Goldman Sachs Group dropped their price objective on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a report on Friday, July 19th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Monday, September 30th. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $173.43.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.